ABSTRACT
Hepatitis C is a health problem worldwide. The World Health Organization estimates that 3% of world's population is infected with hepatitis C virus (HCV). In haemodialysis patients, the prevalence reaches 80% in some countries. In Morocco, HCV prevalence is 32% according to the Moroccan register of dialysis. The natural history of hepatitis C infection in chronic haemodialysis patients is characterized by a silent evolution. There are different methods to diagnose HCV and they are becoming increasingly sensitive. There are indirect tests for antibodies to HCV: these are reproducible but false negatives are common and there is direct testing of viral RNA: this is more sensitive but not always available and is more expensive. The use of these tests has been categorized through new recommendations from learned societies. However, the evaluation of liver disease is still controversial and liver biopsy remains the gold standard. This paper reviews the approaches for diagnosing and evaluating hepatitis C in haemodialysis patients.
Subject(s)
Hepatitis C/complications , Hepatitis C/diagnosis , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/therapy , Renal Dialysis , Enzyme-Linked Immunosorbent Assay/methods , Humans , Polymerase Chain Reaction/methodsABSTRACT
Hepatitis C is a health problem worldwide. The World Health Organizion world's population is infected with hepatitis C virus [HCV]. In haemodialysis patients, the prevalence reaches 80% in some countries. In Morocco/ HCV prevalence is 32% according to the Moroccan register of dialysis. The natural history of hepatitis C infection in chronic haemodialysis patients is characterized by a silent evolution. There are different methods to diagnose HCV and they are becoming increasingly sensitive. There are indirect tests for antibodies to HCV: these are reproducible but false negatives are common and there is direct testing of viral RNA: this is more sensitive but not always available and Is more expensive. The use of these tests has been categorized through new recommendations from learned societies. However, the evaluation of liver disease is still controversial and liver biopsy remains the gold standard. This paper reviews the approaches for diagnosing and evaluating hepatitis C in haemodialysis patients
